These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35028272)

  • 41. A new gel formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis: the Cystadrops OCT-1 study.
    Labbé A; Baudouin C; Deschênes G; Loirat C; Charbit M; Guest G; Niaudet P
    Mol Genet Metab; 2014 Mar; 111(3):314-320. PubMed ID: 24440466
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cysteamine in renal transplantation: A report of two patients with nephropathic cystinosis and the successful re-initiation of cysteamine therapy during the immediate post-transplant period.
    Berryhill A; Bhamre S; Chaudhuri A; Concepcion W; Grimm PC
    Pediatr Transplant; 2016 Feb; 20(1):141-5. PubMed ID: 26477696
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Parenchymal organ cystine depletion with long-term cysteamine therapy.
    Gahl WA; Charnas L; Markello TC; Bernardini I; Ishak KG; Dalakas MC
    Biochem Med Metab Biol; 1992 Dec; 48(3):275-85. PubMed ID: 1476793
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship between age at initiation of cysteamine treatment, adherence with therapy, and glomerular kidney function in infantile nephropathic cystinosis.
    Nießl C; Boulesteix AL; Oh J; Palm K; Schlingmann P; Wygoda S; Haffner D; Wühl E; Tönshoff B; Buescher A; Billing H; Hoppe B; Zirngibl M; Kettwig M; Moeller K; Acham-Roschitz B; Arbeiter K; Bald M; Benz M; Galiano M; John-Kroegel U; Klaus G; Marx-Berger D; Moser K; Mueller D; Patzer L; Pohl M; Seitz B; Treikauskas U; von Vigier RO; Gahl WA; Hohenfellner K
    Mol Genet Metab; 2022 Aug; 136(4):268-273. PubMed ID: 35835062
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of topical cysteamine in nephropathic cystinosis.
    Al-Hemidan A; Shoughy SS; Kozak I; Tabbara KF
    Br J Ophthalmol; 2017 Sep; 101(9):1234-1237. PubMed ID: 28057644
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of NACA and diNACA in human cystinosis fibroblast cell cultures as potential treatments for cystinosis.
    Hector E; Cairns D; Michael Wall G
    Orphanet J Rare Dis; 2022 Jun; 17(1):231. PubMed ID: 35710564
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparison of the effectiveness of cysteamine and phosphocysteamine in elevating plasma cysteamine concentration and decreasing leukocyte free cystine in nephropathic cystinosis.
    Smolin LA; Clark KF; Thoene JG; Gahl WA; Schneider JA
    Pediatr Res; 1988 Jun; 23(6):616-20. PubMed ID: 3393396
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis.
    Levtchenko EN; van Dael CM; de Graaf-Hess AC; Wilmer MJ; van den Heuvel LP; Monnens LA; Blom HJ
    Pediatr Nephrol; 2006 Jan; 21(1):110-3. PubMed ID: 16252107
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cysteamine therapy for children with nephropathic cystinosis.
    Gahl WA; Reed GF; Thoene JG; Schulman JD; Rizzo WB; Jonas AJ; Denman DW; Schlesselman JJ; Corden BJ; Schneider JA
    N Engl J Med; 1987 Apr; 316(16):971-7. PubMed ID: 3550461
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical and neurophysiological characterization of early neuromuscular involvement in children and adolescents with nephropathic cystinosis.
    Elkhateeb N; Selim R; Soliman NA; Atia FM; Abouelwoun II; Elmonem MA; Helmy R
    Pediatr Nephrol; 2022 Jul; 37(7):1555-1566. PubMed ID: 34791528
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multinucleated podocytes as a clue to diagnosis of juvenile nephropathic cystinosis.
    Ogata A; Deki S; Uchimura T; Inaba A; Otani M; Ito S
    Pediatr Nephrol; 2024 Feb; 39(2):609-612. PubMed ID: 37572116
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of enteric-coated cysteamine bitartrate in healthy adults: a pilot study.
    Gangoiti JA; Fidler M; Cabrera BL; Schneider JA; Barshop BA; Dohil R
    Br J Clin Pharmacol; 2010 Sep; 70(3):376-82. PubMed ID: 20716238
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cystinosis: a new perspective.
    Veys KR; Besouw MT; Pinxten AM; Dyck MV; Casteels I; Levtchenko EN
    Acta Clin Belg; 2016 Jun; 71(3):131-7. PubMed ID: 25560059
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A potential new prodrug for the treatment of cystinosis: design, synthesis and in-vitro evaluation.
    McCaughan B; Kay G; Knott RM; Cairns D
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1716-9. PubMed ID: 18249536
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evolution of ocular manifestations in nephropathic cystinosis: a long-term study of a population treated with cysteamine.
    Dureau P; Broyer M; Dufier JL
    J Pediatr Ophthalmol Strabismus; 2003; 40(3):142-6. PubMed ID: 12795432
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcome of infantile nephropathic cystinosis depends on early intervention, not genotype: A multicenter sibling cohort study.
    Veys K; Zadora W; Hohenfellner K; Bockenhauer D; Janssen MCH; Niaudet P; Servais A; Topaloglu R; Besouw M; Novo R; Haffner D; Kanzelmeyer N; Pape L; Wühl E; Harms E; Awan A; Sikora P; Ariceta G; van den Heuvel B; Levtchenko E
    J Inherit Metab Dis; 2023 Jan; 46(1):43-54. PubMed ID: 36117148
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nephropathic cystinosis in children: An overlooked disease.
    Soliman NA; El-Baroudy R; Rizk A; Bazaraa H; Younan A
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):436-42. PubMed ID: 19414947
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic Studies of Cysteamine Bitartrate Delayed-Release.
    Dohil R; Rioux P
    Clin Pharmacol Drug Dev; 2013 Apr; 2(2):178-85. PubMed ID: 27121672
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early oral cysteamine therapy for nephropathic cystinosis.
    Gahl WA
    Eur J Pediatr; 2003 Dec; 162 Suppl 1():S38-41. PubMed ID: 14610675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. N-acetyl-cysteine is associated to renal function improvement in patients with nephropathic cystinosis.
    Pache de Faria Guimaraes L; Seguro AC; Shimizu MH; Lopes Neri LA; Sumita NM; de Bragança AC; Aparecido Volpini R; Cunha Sanches TR; Macaferri da Fonseca FA; Moreira Filho CA; Vaisbich MH
    Pediatr Nephrol; 2014 Jun; 29(6):1097-102. PubMed ID: 24326786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.